Literature DB >> 25425684

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Kevin W Song1, Meletios A Dimopoulos2, Katja C Weisel3, Philippe Moreau4, Antonio Palumbo5, Andrew Belch6, Stephen Schey7, Pieter Sonneveld8, Lars Sternas9, Xin Yu9, Ramesh Amatya10, Mara S Monzini9, Mohamed Zaki9, Christian Jacques9, Jesus San Miguel11.   

Abstract

Entities:  

Keywords:  Pomalidomide; multiple myeloma; quality of life

Mesh：

Substances：

Year:  2014        PMID： 25425684      PMCID： PMC4803120          DOI： 10.3324/haematol.2014.112557

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.

Authors:  Adrian Alegre; Albert Oriol-Rocafiguera; Jose Garcia-Larana; Maria-Victoria Mateos; Anna Sureda; Carmen Martinez-Chamorro; Maria Teresa Cibeira; Beatriz Aguado; Robert Knight; Barbara Rosettani
Journal:  Leuk Lymphoma       Date:  2012-03-01

2.  Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma.

Authors:  Ann Kristin Kvam; Peter M Fayers; Finn Wisloff
Journal:  Eur J Haematol       Date:  2011-07-26       Impact factor: 2.997

3.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

4.  Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners.

Authors:  Alex Molassiotis; Barbara Wilson; Susan Blair; Tracy Howe; James Cavet
Journal:  Psychooncology       Date:  2011-01       Impact factor: 3.894

5.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

6.  Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.

Authors:  Floortje Mols; Simone Oerlemans; Allert H Vos; Ad Koster; Silvia Verelst; Pieter Sonneveld; Lonneke V van de Poll-Franse
Journal:  Eur J Haematol       Date:  2012-08-01       Impact factor: 2.997

7.  Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.

Authors:  Kathrin Strasser-Weippl; Heinz Ludwig
Journal:  Eur J Haematol       Date:  2008-07-11       Impact factor: 2.997

8.  Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

Authors:  Irina Proskorovsky; Philip Lewis; Cathy D Williams; Karin Jordan; Charalampia Kyriakou; Jack Ishak; Faith E Davies
Journal:  Health Qual Life Outcomes       Date:  2014-03-11       Impact factor: 3.186

Review 9.  Association of response endpoints with survival outcomes in multiple myeloma.

Authors:  S Lonial; K C Anderson
Journal:  Leukemia       Date:  2013-07-19       Impact factor: 11.528

Review 10.  Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

Authors:  M A Dimopoulos; X Leleu; A Palumbo; P Moreau; M Delforge; M Cavo; H Ludwig; G J Morgan; F E Davies; P Sonneveld; S A Schey; S Zweegman; M Hansson; K Weisel; M V Mateos; T Facon; J F S Miguel
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528
View more
  9 in total

1.  Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.

Authors:  Francesco Sparano; Michele Cavo; Pasquale Niscola; Tommaso Caravita; Fabio Efficace
Journal:  Support Care Cancer       Date:  2018-03-20       Impact factor: 3.603

Review 2.  Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.

Authors:  Despina Fotiou; Maria Gavriatopoulou; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Ther Adv Hematol       Date:  2022-05-13

3.  Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Authors:  S Ailawadhi; J R Mikhael; B R LaPlant; K M Laumann; S Kumar; V Roy; D Dingli; P L Bergsagel; F K Buadi; S V Rajkumar; R Fonseca; M A Gertz; P Kapoor; T Sher; S R Hayman; A K Stewart; A Dispenzieri; R A Kyle; W I Gonsalves; C B Reeder; Y Lin; R S Go; N Leung; T Kourelis; J A Lust; S J Russell; A A Chanan-Khan; M Q Lacy
Journal:  Leukemia       Date:  2017-09-01       Impact factor: 11.528

4.  Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Authors:  Meletios A Dimopoulos; Antonio Palumbo; Paolo Corradini; Michele Cavo; Michel Delforge; Francesco Di Raimondo; Katja C Weisel; Albert Oriol; Markus Hansson; Angelo Vacca; María Jesús Blanchard; Hartmut Goldschmidt; Chantal Doyen; Martin Kaiser; Mario Petrini; Pekka Anttila; Anna Maria Cafro; Reinier Raymakers; Jesus San-Miguel; Felipe de Arriba; Stefan Knop; Christoph Röllig; Enrique M Ocio; Gareth Morgan; Neil Miller; Mathew Simcock; Teresa Peluso; Jennifer Herring; Lars Sternas; Mohamed H Zaki; Philippe Moreau
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

5.  Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.

Authors:  Dipenkumar Modi; Hirva Mamdani; Theresa Vettese
Journal:  Am J Med Sci       Date:  2015-09       Impact factor: 2.378

6.  Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Authors:  Katja Weisel; Heinz Ludwig; Achim Rieth; Andrea Lebioda; Hartmut Goldschmidt
Journal:  Qual Life Res       Date:  2019-09-24       Impact factor: 4.147

7.  Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Authors:  Michel Delforge; Nina Shah; Jesús San F Miguel; Julia Braverman; Devender S Dhanda; Ling Shi; Shien Guo; Peiwen Yu; Weiqin Liao; Timothy B Campbell; Nikhil C Munshi
Journal:  Blood Adv       Date:  2022-02-22

8.  The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Authors:  Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

Review 9.  Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Authors:  Rafael Ríos-Tamayo; Agustín Martín-García; Carolina Alarcón-Payer; Dolores Sánchez-Rodríguez; Ana María Del Valle Díaz de la Guardia; Carlos Gustavo García Collado; Alberto Jiménez Morales; Manuel Jurado Chacón; José Cabeza Barrera
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.